1. Gorbunova V. A., Artamonova E. V., Breder V. V., Laktionov K. K., Moiseenko F. V., Reutova E. V., Sakaeva D. D. Prakticheskie rekomendatsii RUSSKO po lekarstvennomu lecheniyu nemelkokletochnogo raka legkogo. (NMRL) Versiya 2020. Zlokachestvennye opukholi. 2020. S. 22–36. Gorbunova V. A., Artamonova E. V., Breder V. V., Laktionov K. K., Moiseenko F. V., Reutova E. V., Sakaeva D. D. Practical RUSSIAN recommendations for drug treatment of non-small cell lung cancer. (NSCLC) Version 2020. Malignant tumors. 2020. P. 22–36.
2. Alatar ML, Gold KA, Kim ES. Evolving treatment paradigms in Non-Small Cell Lung Cancer. Clinical Oncology 2009; 12, N 2: 29–43.
3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016; 375 (19): 1823–1833.
4. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced NSCLC with PD-L1 TS > 50 %. WCLC 2017, OA 17.06, presented 18.10.2017.
5. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Progression after the next line of therapy (PFS 2) and updated OS among patients with advanced NSCLC and PD-L1 TPS > 50 % enrolled in KEYNOTE-024. ASCO 2017, abstract 9000.